Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The price a stock trades at can drastically impact your overall returns. If you wait for a top growth stock to come down to a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey ...

After reducing its guidance last month, Eli ... was led by its GLP-1 drugs. For the quarter, revenue for Mounjaro soared 60% year over year to $3.5 billion, while revenue for Zepbound surged ...

Sales of the company’s GLP-1 drugs are still red-hot. But does this mean a rally in Eli Lilly ... that Zepbound provided 47% greater relative weight loss compared to Wegovy. Lilly has also ...

On the top-line, Lilly’s revenue grew by 45%, a brisk pace that was in line with expectations. Earnings more than doubled, beating analyst estimates by 6%. Mounjaro and Zepbound, the company’s ...